JGJulian Glandorf

Julian Glandorf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julian Glandorf has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating Perfusion Quantification for Phase‐Resolved Functional Lung MRI Using Gaussian Filtering

    by Kirsten J. Schmidt, Andreas Voskrebenzev, Julian M. W. Glandorf, Marius M. Klein, Lea Behrendt, Frank Wacker, Jens Vogel‐Claussen, Filip Klimeš

    Phase‐resolved functional lung (PREFUL) MRI enables contrast‐free lung perfusion quantification (Q Quant ). Current quantification uses a single median value per slice of maximal blood exchange fraction (ΔS), which limits regional assessment, whereas regional ΔS causes artifacts. This retrospective study aims to optimize Q Quant by applying Gaussian filtering to ΔS to improve intrascan/interscan repeatability in healthy volunteers, while evaluating whether the optimized Q Quant retains agreement with dynamic contrast‐enhanced (DCE) MRI in chronic obstructive pulmonary disease (COPD) and chronic thromboembolic pulmonary hypertension (CTEPH) patients and exhibits a physiologically plausible gravity‐dependent perfusion gradient. Analysis was performed on 29 healthy subjects (11 female, age: 19–33 years), 20 COPD patients (three female, age: 46–76 years) and 15 CTEPH patients (six female, age: 44–82 years), scanned at 1.5 T. Healthy subjects underwent four PREFUL scans in two sessions. Patients just underwent one PREFUL and DCE scan. Q Quant maps were calculated while applying different Gaussian filter options to ΔS. In patients, PREFUL‐derived Q Quant maps were coregistered to DCE‐derived pulmonary blood flow (PBF) maps for global and voxel‐wise correlations. In healthy subjects, the gravity‐dependent perfusion gradient was quantified by linear regression of slice‐wise Q Quant across five coronal slices. Gaussian filtering ΔS with σ = 1.5 improved intrascan and interscan repeatability in healthy subjects (mean bias: ≤ 2.94 mL/100 mL; Cohen's d : 0.2) compared with the current slice median setting (mean bias: ≥ 3.75 mL/100 mL; Cohen's d : 0.68). Correlations with PBF remained stable after filtering (σ = 1.5) in COPD (filtered vs. default ΔS: global r = 0.57 vs. r = 0.59, voxel‐wise r = 0.32 vs. r = 0.32) and CTEPH (global r = 0.32 vs. r = 0.28, voxel‐wise r = 0.40 vs. r = 0.41), all significant except global CTEPH. The filtered Q Quant maps showed a significant gravity‐dependent perfusion gradient (ΔS filtered σ = 1.5) of 1.47 mL/min/100 mL/cm. Gaussian filtering ΔS with σ = 1.5 improved Q Quant repeatability while preserving DCE‐MRI agreement and is therefore recommended. The observed gravity‐dependent perfusion gradient confirms physiological plausibility, supporting potential in clinical use.

  • Phase-Resolved Functional Lung MRI–derived Pulmonary Arterial Pulse Wave Velocity Correlates with 12-Month Mortality in Participants with Pulmonary Hypertension: A Post Hoc Analysis of a Multicenter Study

    by Marius M. Klein, Andreas Voskrebenzev, Filip Klimeš, Milan Speth, Robin A. Müller, Karen M. Olsson, Julian Glandorf, Claus P. Heußel, Ekkehard Grünig, Henning Gall, et al.

    Pulmonary artery pulse wave velocity derived from phase-resolved functional lung MRI was higher in pulmonary hypertension and independently associated with right ventricular function and 12-month mortality.

  • Open Access

    Analysis of Pulsatile Vessel Expansion in Healthy, COPD ‐ and PH ‐Patients Using Dynamic Vessel Segmentation in Free‐Breathing Lung MRI

    by Julian Glandorf, Marius M. Klein, Filip Klimeš, Agilo Luitger Kern, Marcel Gutberlet, Jens M. Hohlfeld, Marius M. Hoeper, Karen M. Olsson, Frank Wacker, Jens Vogel‐Claussen, et al.

    Background: The pulsatile expansion of pulmonary vessels carries dynamic cardiopulmonary information that may reveal disease earlier than structural changes alone. Purpose: To test (i) intra‐ and inter‐scan repeatability of dynamic vessel metrics in healthy subjects, and (ii) whether chronic obstructive pulmonary disease (COPD) and postcapillary pulmonary hypertension (PH) exhibit disease‐specific differences. Study Type: Retrospective, multi‐cohort feasibility study with repeatability sub‐study. Subjects: Healthy: 29 (11 female), COPD: 52 (15 female), PH: 25 (15 female) with isolated postcapillary PH. Fieldstrength/Sequence: 1.5T, free‐breathing spoiled gradient‐echo sequence, TE = 0.82 ms, TR = 3 ms, flip angle = 5°. Assessment: 2D U‐Nets segmented pulmonary vessels throughout each series of 250 images. Dynamic metrics included the coefficient of variation (CV) of vessel area and CV of vessel signal. Delay between vessel signal and vessel expansion as %‐of‐RR‐interval (SE‐delay) together with the heart rate and lung area were calculated. Statistical Tests: Repeatability: Friedman; intraclass correlation coefficient (ICC); standard error of measurement (SEM) and the minimal detectable change (MDC). Group comparisons: Kruskal–Wallis and multiple linear regression. p < 0.05 was considered significant. Results: Only the heart rate and the SE‐delay presented significant changes across repetitive scans. Differences in Bland–Altman plots were evenly distributed across the range of measurements and symmetrically scattered around zero within 95% confidence intervals (mean bias 0.08%–5.12%). Across cohorts, CV vessel area and CV lung area differed significantly, showing lowest variability in COPD (2.67%; 7.03%) and highest in PH (4.58%; 16.74%). SE‐delay was significantly prolonged in COPD (81.98%) compared to PH (67.20%) and healthy participants (62.97%). Cohort status (Healthy/COPD/PH) remained the strongest significant predictor for all parameters after adjustment ( F ‐values 4.62–34.04), while age and gender had no significant influence ( p > 0.391; p > 0.069). Data Conclusion: Free‐breathing lung MRI with automated vessel segmentation reveals distinct hemodynamic characteristics in COPD and PH. This method shows potential as a sensitive non‐invasive tool for detection, phenotyping, and treatment monitoring in pulmonary pathology. Evidence Level: 3. Technical Efficacy: 2.


  • Open Access

    Improving necrosis estimation in MR-guided prostate focused ultrasound ablations with a probabilistic thermal dose model

    by Simon Schröer, Julian Glandorf, Daniel Düx, Dominik Horstmann, Moritz Gutt, Othmar Belker, Inga Peters, Susanne Hellms, Frank Wacker, Bennet Hensen, et al.


  • Phase-resolved Functional Lung MRI Reveals Distinct Lung Perfusion Phenotype in Children and Adolescents with Post–COVID-19 Condition

    by Gesa H. Pöhler, Andreas Voskrebenzev, Marc-Luca Heinze, Valentina Skeries, Filip Klimeš, Julian Glandorf, Jan Eckstein, Nigar Babazade, Marius Wernz, Alexander Pfeil, et al.

    Phase-resolved functional lung MRI–derived parameters depicted pulmonary perfusion abnormalities in children and adolescents with post–COVID-19 condition and correlated with heart rate and chronic fatigue severity.


  • Open Access

    Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial

    by Elisabeth Bahlmann-Kroll, Sebastian Häckl, Stefanie Kramer, Vera Christine Wulfmeyer, Julian Glandorf, Jessica Kaufeld, Armin Koch, Dagmar Hartung, Bernhard M W Schmidt, Kai Schmidt-Ott, et al.

    Introduction Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary condition that causes the formation of cysts primarily in the kidneys. The continuous growth of multiple cysts leads to the destruction of functional parenchyma, which may progress to end-stage kidney disease. Tolvaptan is the only drug specifically approved for slowing down the progression of ADPKD. Sodium-glucose transporter 2 inhibitors might provide additional benefits but there is currently no information on safety and outcome effects of SGLT2i in patients with ADPKD, as these patients were excluded in SGLT2i trials. In particular, there has been speculation that SGLT2i might increase cyst growth and accelerate the loss of kidney function in ADPKD. The EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring the total kidney volume and the loss of kidney function. Methods and analysis This is an investigator-initiated, double-blind, single-centre, placebo-controlled, randomised clinical trial including patients with rapidly progressive ADPKD (n=44). Participants will be randomly allocated (1:1) to receive a daily dose of either empagliflozin (10 mg/day) or placebo for 18 months. Patients will be stratified according to concomitant tolvaptan use. The primary endpoint is the progression of cystic kidney growth by monitoring MRI-based changes in total kidney volume and the secondary endpoint is the change in glomerular filtration rate. Additional endpoints include changes in copeptin levels, albuminuria and blood pressure. Ethics and dissemination The protocol has been approved by the German Federal Institute for Drugs and Medical Devices (BfArM) after review by the independent ethics committee Landesarztekammer Rheinland-Pfalz. Participation in this study will be voluntary and informed consent will be obtained. Regardless of the outcome, the results will be disseminated through a peer-reviewed international medical journal. Trial registration numbers EU-CT number 2023-505890-34-00, NCT06391450.


  • Open Access

    MRI-compatible and sensorless haptic feedback for cable-driven medical robotics to perform teleoperated needle-based interventions

    by Ivan Vogt, Marcel Eisenmann, Anton Schlünz, Robert Kowal, Daniel Düx, Maximilian Thormann, Julian Glandorf, Seben Sena Yerdelen, Marilena Georgiades, Robert Odenbach, et al.

    Purpose: Surgical robotics have demonstrated their significance in assisting physicians during minimally invasive surgery. Especially, the integration of haptic and tactile feedback technologies can enhance the surgeon’s performance and overall patient outcomes. However, the current state-of-the-art lacks such interaction feedback opportunities, especially in robotic-assisted interventional magnetic resonance imaging (iMRI), which is gaining importance in clinical practice, specifically for percutaneous needle punctures. Methods: The cable-driven ‘Micropositioning Robotics for Image-Guided Surgery’ (µRIGS) system utilized the back-electromotive force effect of the stepper motor load to measure cable tensile forces without external sensors, employing the TMC5160 motor driver. The aim was to generate a sensorless haptic feedback (SHF) for remote needle advancement, incorporating collision detection and homing capabilities for internal automation processes. Three different phantoms capable of mimicking soft tissue were used to evaluate the difference in force feedback between manual needle puncture and the SHF, both technically and in terms of user experience. Results: The SHF achieved a sampling rate of 800 Hz and a mean force resolution of 0.26 ± 0.22 N, primarily dependent on motor current and rotation speed, with a mean maximum force of 15 N. In most cases, the SHF data aligned with the intended phantom-related force progression. The evaluation of the user study demonstrated no significant differences between the SHF technology and manual puncturing. Conclusion: The presented SHF of the µRIGS system introduced a novel MR-compatible technique to bridge the gap between medical robotics and interaction during real-time needle-based interventions.


  • Open Access

    Estimation of Cerebral Blood Flow Using the Pulse Wave Amplitude in Brain MRI

    by Julian Glandorf, Filip Klimeš, Agilo Luitger Kern, Andreas Voskrebenzev, Marcel Gutberlet, Norman Kornemann, Frank Wacker, Mike P. Wattjes, Jens Vogel-Claussen

  • PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study

    by Martha Dohna, Andreas Voskrebenzev, Filip Klimeš, Till F. Kaireit, Julian Glandorf, Sophia T. Pallenberg, Felix C. Ringshausen, Gesine Hansen, Diane Miriam Renz, Frank Wacker, et al.

    Purpose To assess the feasibility of monitoring the effects of elexacaftor-tezacaftor-ivacaftor (ETI) therapy on lung ventilation and perfusion in people with cystic fibrosis (CF), using phase-resolved functional lung (PREFUL) MRI. Materials and Methods This secondary analysis of a multicenter prospective study was carried out between August 2020 and March 2021 and included participants 12 years or older with CF who underwent PREFUL MRI, spirometry, sweat chloride test, and lung clearance index assessment before and 8-16 weeks after ETI therapy. For PREFUL-derived ventilation and perfusion parameter extraction, two-dimensional coronal dynamic gradient-echo MR images were evaluated with an automated quantitative pipeline. T1- and T2-weighted MR images and PREFUL perfusion maps were visually assessed for semiquantitative Eichinger scores. Wilcoxon signed rank test compared clinical parameters and PREFUL values before and after ETI therapy. Correlation of parameters was calculated as Spearman ρ correlation coefficient. Results Twenty-three participants (median age, 18 years [IQR: 14-24.5 years]; 13 female) were included. Quantitative PREFUL parameters, Eichinger score, and clinical parameters (lung clearance index = 21) showed significant improvement after ETI therapy. Ventilation defect percentage of regional ventilation decreased from 18% (IQR: 14%-25%) to 9% (IQR: 6%-17%) (P = .003) and perfusion defect percentage from 26% (IQR: 18%-36%) to 19% (IQR: 13%-24%) (P = .002). Areas of matching normal (healthy) ventilation and perfusion increased from 52% (IQR: 47%-68%) to 73% (IQR: 61%-83%). Visually assessed perfusion scores did not correlate with PREFUL perfusion (P = .11) nor with ventilation-perfusion match values (P = .38). Conclusion The study demonstrates the feasibility of PREFUL MRI for semiautomated quantitative assessment of perfusion and ventilation changes in response to ETI therapy in people with CF. Keywords: Pediatrics, MR-Functional Imaging, Pulmonary, Lung, Comparative Studies, Cystic Fibrosis, Elexacaftor-Tezacaftor-Ivacaftor Therapy, Fourier Decomposition, PREFUL, Free-Breathing Proton MRI, Pulmonary MRI, Perfusion, Functional MRI, CFTR, Modulator Therapy, Kaftrio Clinical trial registration no. NCT04732910 Supplemental material is available for this article. © RSNA, 2024.


  • Open Access

    Feasibility, Repeatability, and Correlation to Lung Function of Phase‐Resolved Functional Lung (PREFUL) MRI‐derived Pulmonary Artery Pulse Wave Velocity Measurements

    by Marius M. Wernz, Andreas Voskrebenzev, Robin A. Müller, Maximilian Zubke, Filip Klimeš, Julian Glandorf, Christoph Czerner, Frank Wacker, Karen M. Olsson, Marius M. Hoeper, et al.

    Background: Pulse wave velocity (PWV) in the pulmonary arteries (PA) is a marker of vascular stiffening. Currently, only phase‐contrast (PC) MRI‐based options exist to measure PA‐PWV.Purpose: To test feasibility, repeatability, and correlation to clinical data of Phase‐Resolved Functional Lung (PREFUL) MRI‐based calculation of PA‐PWV.Study Type: Retrospective.Subjects: 79 (26 female) healthy subjects (age range 19–78), 58 (24 female) patients with chronic obstructive pulmonary disease (COPD, age range 40–77), 60 (33 female) patients with suspected pulmonary hypertension (PH, age range 28–85).Sequence: 2D spoiled gradient echo, 1.5T.Assessment: PA‐PWV was measured from PREFUL‐derived cardiac cycles based on the determination of temporal and spatial distance between lung vasculature voxels using a simplified (sPWV) method and a more comprehensive (cPWV) method including more elaborate distance calculation. For 135 individuals, PC MRI‐based PWV (PWV‐QA) was measured.Statistical Tests: Intraclass‐correlation‐coefficient (ICC) and coefficient of variation (CoV) were used to test repeatability. Nonparametric tests were used to compare cohorts. Correlation of sPWV/cPWV, PWV‐QA, forced expiratory volume in 1 sec (FEV1) %predicted, residual volume (RV) %predicted, age, and right heart catheterization (RHC) data were tested. Significance level α = 0.05 was used.Results: sPWV and cPWV showed no significant differences between repeated measurements (P‐range 0.10–0.92). CoV was generally lower than 15%. COPD and PH patients had significantly higher sPWV and cPWV than healthy subjects. Significant correlation was found between sPWV or cPWV and FEV1%pred. (R = −0.36 and R = −0.44), but not with RHC (P‐range −0.11 − 0.91) or age (P‐range 0.23–0.89). Correlation to RV%pred. was significant for cPWV (R = 0.42) but not for sPWV (R = 0.34, P = 0.055). For all cohorts, sPWV and cPWV were significantly correlated with PWV‐QA (R = −0.41 and R = 0.48).Data Conclusion: PREFUL‐derived PWV is feasible and repeatable. PWV is increased in COPD and PH patients and correlates to airway obstruction and hyperinflation.Level of Evidence: 3Technical Efficacy: Stage 2